The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Dose-Finding Study of E7070 in Combination With Irinotecan
Official Title: Phase I Dose-Finding Study of E7070 in Combination With Irinotecan
Study ID: NCT00060567
Brief Summary: E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Boston, Massachusetts, United States
Name: Eisai Medical Services
Affiliation: Eisai Inc.
Role: STUDY_DIRECTOR